

Flore Sicre de Fontbrune

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8138629/publications.pdf>

Version: 2024-02-01

53
papers

1,815
citations

471509

17
h-index

276875

41
g-index

54
all docs

54
docs citations

54
times ranked

3010
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms. <i>Leukemia</i> , 2022, 36, 126-137.	7.2	10
2	RNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea. <i>Blood Advances</i> , 2022, 6, 2805-2811.	5.2	6
3	Successful cefiderocol therapy of severe infections due to difficult-to-treat <i>Pseudomonas aeruginosa</i> in two allogeneic hematopoietic stem cell transplantation recipients. <i>Annals of Hematology</i> , 2022, , 1.	1.8	3
4	Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 33-43.	2.4	5
5	Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1365-1372.	2.4	3
6	Prospective external validation of biomarkers to predict acute graft-versus-host disease severity. <i>Blood Advances</i> , 2022, 6, 4763-4772.	5.2	4
7	Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation. <i>Haematologica</i> , 2021, 106, 2374-2383.	3.5	14
8	Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 38-49.	2.4	9
9	Expansion of Circulating CD49b+LAG3+ Type 1 Regulatory T Cells in Human Chronic Graft-Versus-Host Disease. <i>Journal of Investigative Dermatology</i> , 2021, 141, 193-197.e2.	0.7	4
10	Treatment for pure red cell aplasia after major ABOâ€incompatible allogeneic stem cell transplantation: a multicentre study. <i>British Journal of Haematology</i> , 2021, 193, 814-826.	2.5	16
11	Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. <i>Lancet Haematology</i> ,the, 2021, 8, e344-e354.	4.6	56
12	Recurrent bacterial infections, but not fungal infections, characterise patients with <i>ELANE</i>-related neutropenia: a French Severe Chronic Neutropenia Registry study. <i>British Journal of Haematology</i> , 2021, 194, 908-920.	2.5	11
13	Immunogenetic, Molecular and Clinical Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2021, 138, 602-602.	1.4	1
14	Risk factors for vascular liver diseases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 410-419.	1.5	4
15	Late-Onset EBV Susceptibility and Refractory Pure Red Cell Aplasia Revealing DADA2. <i>Journal of Clinical Immunology</i> , 2020, 40, 948-953.	3.8	14
16	Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2115-2120.	2.0	4
17	Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. <i>PLoS ONE</i> , 2020, 15, e0237497.	2.5	21
18	One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096613.	2.5	24

#	ARTICLE	IF	CITATIONS
19	Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial. <i>Blood</i> , 2020, 135, 227-229.	1.4	20
20	Next-Generation Sequencing in Myeloid Neoplasm-Associated Sweet's Syndrome Demonstrates Clonal Relation between Malignant Cells and Skin-Infiltrating Neutrophils. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1873-1876.e5.	0.7	23
21	Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report. <i>Annals of Hematology</i> , 2020, 99, 897-898.	1.8	1
22	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1160-1170.	2.0	9
23	Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 978-984.	2.0	49
24	Automated quantification of Epstein-Barr virus in whole blood for post-transplant lymphoproliferative disorders monitoring. <i>Virology Journal</i> , 2020, 17, 20.	3.4	2
25	The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2020, 135, 912-920.	1.4	73
26	Lenograstim and Filgrastim Have a Similar Efficacy and Safety Profile in the Treatment of Chronic Neutropenia. a Study for the French SCN Registry:. <i>Blood</i> , 2020, 136, 17-18.	1.4	2
27	Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease in Patients Who Received Anti-CD20 after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2490-2500.	2.0	9
28	Germline DDX41 mutations define a significant entity within adult MDS/AML patients. <i>Blood</i> , 2019, 134, 1441-1444.	1.4	153
29	Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. <i>Leukemia and Lymphoma</i> , 2019, 60, 2802-2805.	1.3	10
30	Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. <i>Blood Advances</i> , 2019, 3, 2424-2435.	5.2	66
31	Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. <i>Nature Communications</i> , 2019, 10, 5695.	12.8	91
32	Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. <i>Blood</i> , 2019, 133, 530-539.	1.4	227
33	Sexual Life, Fertility and Ovarian Function in Women after Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2019, 134, 3301-3301.	1.4	0
34	Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria. <i>Seminars in Hematology</i> , 2018, 55, 124-129.	3.4	19
35	Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers. <i>Haematologica</i> , 2018, 103, e103-e105.	3.5	16
36	Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. <i>Haematologica</i> , 2018, 103, 212-220.	3.5	62

#	ARTICLE	IF	CITATIONS
37	A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. <i>Blood</i> , 2018, 131, 717-732.	1.4	240
38	Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. <i>Blood</i> , 2018, 132, 750-754.	1.4	44
39	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. <i>Haematologica</i> , 2018, 103, 1278-1287.	3.5	129
40	A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 4007-4007.	1.4	1
41	Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1206-1211.	2.0	70
42	APRIL levels are associated with disease activity in human chronic graft-versus-host disease. <i>Haematologica</i> , 2016, 101, e312-e315.	3.5	9
43	Influence of Previous Inflammatory Bowel Disease on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Matched-Pair Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1721-1724.	2.0	11
44	Nationwide Survey on the Use of Eltrombopag in Patients with Severe Aplastic Anemia: Report on Behalf of the French Reference Center for Aplastic Anemia. <i>Blood</i> , 2016, 128, 2684-2684.	1.4	1
45	Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib. <i>Blood</i> , 2016, 128, 4561-4561.	1.4	10
46	Reactive Hemophagocytic Syndrome after Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). <i>Blood</i> , 2016, 128, 4617-4617.	1.4	1
47	Romiplostim in Patients Undergoing Allogeneic Stem Cell Transplantation: Results of a Phase I/II Multicenter Trial. <i>Blood</i> , 2016, 128, 65-65.	1.4	4
48	Clinical Characteristics, Biological Markers and Comorbidity Indexes As Predictors of Transplant-Related Mortality after Allogeneic Hematopoietic Stem Cell Transplantation: Which One Should We Choose?. <i>Blood</i> , 2016, 128, 3478-3478.	1.4	0
49	Evaluation of Graft Versus Host Disease and Relapse Free Survival As Novel Endpoint in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Joint Naples-Paris Study. <i>Blood</i> , 2016, 128, 2285-2285.	1.4	15
50	Aplastic Anemia in the Context of Hemolytic Paroxysmal Nocturnal Hemoglobinuria: Feasibility of Antibody-Based Intensive Immunosuppression during Eculizumab Treatment. <i>Blood</i> , 2016, 128, 5074-5074.	1.4	0
51	Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. <i>Blood</i> , 2015, 125, 775-783.	1.4	122
52	Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy. <i>Transplantation</i> , 2015, 99, 1953-1959.	1.0	110
53	GLCC11 and Glucocorticoid Receptor Genetic Diversity and Response to Glucocorticoid-Based Treatment of Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1246-1250.	2.0	7